JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives

Abstract. The 2011 approval of ruxolitinib ushered in the Janus kinase (JAK) inhibitor era in the treatment of myelofibrosis (MF), and 2019 saw the US approval of fedratinib. The first therapeutic agents approved by regulatory authorities for MF, these drugs attenuate the overactive JAK-signal trans...

Full description

Bibliographic Details
Main Authors:	Prithviraj Bose, Srdan Verstovsek
Format:	Article
Language:	English
Published:	Wolters Kluwer 2020-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000424

Similar Items

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
by: Prithviraj Bose, et al.
Published: (2020-10-01)

Treatment and management of myelofibrosis in the era of JAK inhibitors
by: Keohane C, et al.
Published: (2013-08-01)

Updates in the management of polycythemia vera and essential thrombocythemia
by: Prithviraj Bose, et al.
Published: (2019-08-01)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
by: Ostojic A, et al.
Published: (2012-03-01)

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
by: Keohane C, et al.
Published: (2013-10-01)

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
by: Andrew T. Kuykendall, et al.
Published: (2020-08-01)

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
by: Srdan Verstovsek, et al.
Published: (2016-12-01)

The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis
by: Martina Barone, et al.
Published: (2020-01-01)

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
by: Randhawa Jasleen, et al.
Published: (2012-08-01)

Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis
by: M. V. Barabanshchikova, et al.
Published: (2016-03-01)

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes
by: Mughal TI, et al.
Published: (2014-01-01)

Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.
by: Taghi Manshouri, et al.
Published: (2019-01-01)

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis
by: Marte Karen Brattås, et al.
Published: (2018-11-01)

Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation
by: Maria Vladimirovna Barabanshikova, et al.
Published: (2019-09-01)

Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis
by: Marco Romano, et al.
Published: (2017-10-01)

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
by: Leonardo Caires dos Santos, et al.
Published: (2011-12-01)

Coexisting BRAF-Mutated Langerhans Cell Histiocytosis and Primary Myelofibrosis with Shared JAK2 Mutation
by: Johanne Marie Holst, et al.
Published: (2021-01-01)

Ruxolitinib as an emerging treatment in myelofibrosis
by: Emanuel RM, et al.
Published: (2013-03-01)

Role of splenectomy in the treatment of myelofibrosis
by: A L Melikian, et al.
Published: (2013-08-01)

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
by: Hans Michael Kvasnicka, et al.
Published: (2018-03-01)

HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis
by: Margaux Sevin, et al.
Published: (2018-04-01)

JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.
by: Giovanni Barosi, et al.
Published: (2013-01-01)

Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis
by: Nikolaos Sousos, et al.
Published: (2020-06-01)

JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden.
by: Paolo Catarsi, et al.
Published: (2015-01-01)

JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia
by: Bárbara da Costa Reis Monte-Mór, et al.
Published: (2007-03-01)

CLINICAL AND LABORATORY FEATURES OF ESSENTIAL THROMBOCYTOSIS AND PRIMARY MYELOFIBROSIS DEPENDING ON JAK2 AND CALR1 MUTATION STATUS
by: E. G. lisina, et al.
Published: (2017-10-01)

Treatment of Myelofibrosis: Old and New Strategies
by: Alessandra Iurlo, et al.
Published: (2017-03-01)

Next Generation Therapeutics for the Treatment of Myelofibrosis
by: Douglas Tremblay, et al.
Published: (2021-04-01)

Mechanisms of myelofibrosis
by: Patterson, Shenia
Published: (2016)

Correction Notice: Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis
Published: (2021-05-01)

Standard care and investigational drugs in the treatment of myelofibrosis
by: Daniela Barraco, et al.
Published: (2019-09-01)

Emerging treatment options for myelofibrosis: focus on pacritinib
by: Chow V, et al.
Published: (2016-05-01)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
by: Gowin KL, et al.
Published: (2015-04-01)

Patients with primary myelofibrosis: treatment and quality of life
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)

Patients with primary myelofibrosis: treatment and quality of life
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)

JAK2V617F mutation in a patient with B-cell chronic lymphocytic leukemia and prefibrotic primary myelofibrosis
by: Ristić Slobodan, et al.
Published: (2015-01-01)

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
by: Stephen Couban, et al.
Published: (2018-09-01)

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
by: Claire N. Harrison, et al.
Published: (2021-05-01)

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
by: Srdan Verstovsek, et al.
Published: (2017-09-01)

Murine Models of Myelofibrosis
by: Sebastien Jacquelin, et al.
Published: (2020-08-01)